APA ציטוט

Freiburghaus, C., Emruli, V. K., Johansson, A., Eskelund, C. W., Grønbæk, K., Olsson, R., . . . Ek, S. (2018). Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity. BMC Cancer.

Citação norma Chicago

Freiburghaus, Catja, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, and Sara Ek. "Bortezomib Prevents Cytarabine Resistance in MCL, Which Is Characterized By Down-regulation of DCK and Up-regulation of SPIB Resulting in High NF-κB Activity." BMC Cancer 2018.

ציטוט MLA

Freiburghaus, Catja, et al. "Bortezomib Prevents Cytarabine Resistance in MCL, Which Is Characterized By Down-regulation of DCK and Up-regulation of SPIB Resulting in High NF-κB Activity." BMC Cancer 2018.